These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10504332)

  • 1. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms.
    Mikhailenko I; Considine W; Argraves KM; Loukinov D; Hyman BT; Strickland DK
    J Cell Sci; 1999 Oct; 112 ( Pt 19)():3269-81. PubMed ID: 10504332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
    Horn IR; van den Berg BM; van der Meijden PZ; Pannekoek H; van Zonneveld AJ
    J Biol Chem; 1997 May; 272(21):13608-13. PubMed ID: 9153209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties.
    Neels JG; van Den Berg BM; Lookene A; Olivecrona G; Pannekoek H; van Zonneveld AJ
    J Biol Chem; 1999 Oct; 274(44):31305-11. PubMed ID: 10531329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
    Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
    J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein.
    Rettenberger PM; Oka K; Ellgaard L; Petersen HH; Christensen A; Martensen PM; Monard D; Etzerodt M; Chan L; Andreasen PA
    J Biol Chem; 1999 Mar; 274(13):8973-80. PubMed ID: 10085143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein.
    Willnow TE; Orth K; Herz J
    J Biol Chem; 1994 Jun; 269(22):15827-32. PubMed ID: 7515061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes.
    Argraves KM; Battey FD; MacCalman CD; McCrae KR; Gåfvels M; Kozarsky KF; Chappell DA; Strauss JF; Strickland DK
    J Biol Chem; 1995 Nov; 270(44):26550-7. PubMed ID: 7592875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site.
    Nielsen MS; Nykjaer A; Warshawsky I; Schwartz AL; Gliemann J
    J Biol Chem; 1995 Oct; 270(40):23713-9. PubMed ID: 7559542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
    Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
    J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
    Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.
    Liu CX; Li Y; Obermoeller-McCormick LM; Schwartz AL; Bu G
    J Biol Chem; 2001 Aug; 276(31):28889-96. PubMed ID: 11384978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor.
    Battey FD; Gåfvels ME; FitzGerald DJ; Argraves WS; Chappell DA; Strauss JF; Strickland DK
    J Biol Chem; 1994 Sep; 269(37):23268-73. PubMed ID: 8083232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
    Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
    J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular fate of LDL receptor family members depends on the cooperation between their ligand-binding and EGF domains.
    Van Hoof D; Rodenburg KW; Van der Horst DJ
    J Cell Sci; 2005 Mar; 118(Pt 6):1309-20. PubMed ID: 15741231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.